ReNerve (ASX: RNV) received an additional AU$139,537 in research and development tax incentives following an assessment of the company's overseas research activities, bringing its total refund to AU$516,606, according to a Friday filing with the Australian bourse.
The company said it is working and developing products aimed to provide a complete range of products for peripheral nerve repair and replacement.
The company's shares were down almost 4% in recent Friday trade, earlier hitting an all-time low.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。